1. Sirolimus Eluting Coronary Stent System with a Biodegradable Polymer
YUKON Choice PC
Sirolimus Eluting Coronary Stent System
with a Biodegradable Polymer

2. Technology Highlights
YUKON Choice PC is manufactured by Translumina Therapeutics in their manufacturing Facility at Pharma City Dehradun. Its a collaboration between Advance Therapeutics and Translumina GmbH, Germany.
This is the first project where a proven technology of a drug Eluting Stent is sourced from Europe and is manufactured in India using international standards .
The technology is proven in large trials in Europe but shall be sourced from India for world.
For the first time, High end machines and layout are created as per the specifications of European guidelines.

3. Translumina GmbH-Germany
Founded in 1998 ,The promoters were in Senior Management positions in Guidant(Now abott) and Boston Scientific.
The company is based at Hechingen ,Germany with state of the art manufacturing facility.
Translumina was the first company to launch a Drug Eluting Stent without a polymer,YUKON Choice, using a innovative technology of in-cath lab coating in
Translumina is marketing its products in India for the last 6 years.All the raw materials for Indian manufacturing shall be provided by Translumina GmbH

4. YUKON Choice PC is a combination of :
- Sirolimus
- Microporous Stent surface
- Biodegradable Polymer Resomer R202S
- Shellac Resin
YUKON Choice PC is a third generation Sirolimus eluting Stent System that combines the synergistic effect of surface modification and biodegradable polymer to create optimum release.
YUKON Choice PC’s Stent surface is coated abluminally with no drug or polymer on the luminal side of the Stent for enhanced safety.

5. less polymeric load compared to other DES
YUKON Choice PC - A generation ahead
less polymeric load compared to other DES
YUKON Choice PC® has microporous surface which enables minimum load of a biodegradable Polymer for optimizing the release kinetics
Micro-pores which act like reservoirs for delivering the drug to the targeted sites use Van-der-Waals forces to control the release- kinetics of the drug

6. YUKON Choice PC - Safety Features
Better Endothelialization-No coating on the Luminal side of the Stent
Biodegradable Polymer-Degrades in 90 days
Less Polymeric Load-1/4th of the polymeric load compared to other DES

7. Drug and Polymer are co-released in 30-45 days
Release Kinetics
Drug and Polymer are co-released in days

8. YUKON Choice PC - Efficacy Vs. Xience & Cypher
ISAR-TEST 4 is the first prospective randomized trial which compares 3 DES i.e.
YUKON Choice PC, Xience and Cypher for their efficacy & safety

9. YUKON Choice PC
ISAR-TEST 4 is the only trial with planned angiographic follow up at 2 years in more than 70% patients

10. ISAR-TEST 4 - Results
YUKON Choice PC proves non-inferior to Xience and Cypher at 3 years follow up published in JACC Sept. 2011

11. ISAR-TEST 4 - Results
YUKON Choice PC proves non-inferior to Xience and Cypher at 3 years follow up published in JACC Sept. 2011

12. ISAR-TEST 4 - Results
YUKON Choice PC shows similar TLR’s compared to Xience and Cypher at 2 years follow up

13. ISAR-TEST 4 - AMI Sub-group
YUKON Choice PC has least polymeric load of a biodegradable polymer and thus is hypothesized to how better results than Xience and Cypher

14. ISAR-TEST 4 - AMI Sub-group
YUKON Choice PC shows better results than Xience and Cypher in AMI patients

15. Yukon Choice PC 4 years follow-up data compared
to first generation DES

16. ISAR-TEST 4 - 3 years follow-up
ISAR-TEST 4 is the only comparative trial of 3 DES, YUKON Choice PC Xience and Cypher, with 3 years follow-up

17. ISAR-TEST 4 - Study Flow

18. ISAR-TEST 4 - Results
YUKON Choice PC is the First DES which has shown statistical significant reduction of Stent Thrombosis by 50% compared to first generation DES.

19. ISAR-TEST 4 - Results
YUKON Choice PC shows 78% reduction in Stent Thrombosis compared to first generation DES.

20. YUKON Choice PC - Excellent Safety Profile
YUKON Choice PC is the First DES which has shown statistical significant reduction in Stent thrombosis compared to first generation DES.
YUKON Choice PC shows 78% reduction in Stent Thrombosis compared to first generation DES.
The unique combination of microporous Stent surface and less biodegradable polymeric load ensures that it becomes a BMS after the drug delivery.
The presence of drug only on the abluminal side ensures healthy endothelialization.
Limited anti-platelet regimen may be required after implantation.